Secondary Modification of S100B Influences Anti Amyloid-β Aggregation Activity and Alzheimer’s Disease Pathology
Open Access
- 1 February 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (3) , 1787
Abstract
Proteinaceous aggregates accumulate in neurodegenerative diseases such as Alzheimer’s Disease (AD), inducing cellular defense mechanisms and altering the redox status. S100 pro-inflammatory cytokines, particularly S100B, are activated during AD, but recent findings reveal an unconventional molecular chaperone role for S100B in hindering Aβ aggregation and toxicity. This suggests a potential protective role for S100B at the onset of Aβ proteotoxicity, occurring in a complex biochemical environment prone to oxidative damage. Herein, we report an investigation in which extracellular oxidative conditions are mimicked to test if the susceptibility of S100B to oxidation influences its protective activities. Resorting to mild oxidation of S100B, we observed methionine oxidation as inferred from mass spectrometry, but no cysteine-mediated crosslinking. Structural analysis showed that the folding, structure, and stability of oxidized S100B were not affected, and nor was its quaternary structure. However, studies on Aβ aggregation kinetics indicated that oxidized S100B was more effective in preventing aggregation, potentially linked to the oxidation of Met residues within the S100:Aβ binding cleft that favors interactions. Using a cell culture model to analyze the S100B functions in a highly oxidative milieu, as in AD, we observed that Aβ toxicity is rescued by the co-administration of oxidized S100B to a greater extent than by S100B. Additionally, results suggest a disrupted positive feedback loop involving S100B which is caused by its oxidation, leading to the downstream regulation of IL-17 and IFN-α2 expression as mediated by S100B.Keywords
Funding Information
- Fundação para a Ciência e Tecnologia (Portugal) (SFRH/PD/BD/142897/2018, BD/06393/2021, UIDB/04046/2020, UIDP/MULTI/04046/2020, GA 101079147)
- European Union (SFRH/PD/BD/142897/2018, BD/06393/2021, UIDB/04046/2020, UIDP/MULTI/04046/2020, GA 101079147)
This publication has 78 references indexed in Scilit:
- Robust shifts in S100a9 expression with aging: A novel mechanism for chronic inflammationScientific Reports, 2013
- Crosstalk of reactive oxygen species and NF-κB signalingCell Research, 2010
- The Calcium-binding Protein S100B Down-regulates p53 and Apoptosis in Malignant MelanomaJournal of Biological Chemistry, 2010
- Molecular mechanism of Thioflavin-T binding to amyloid fibrilsBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2010
- Small Molecules Bound to Unique Sites in the Target Protein Binding Cleft of Calcium-Bound S100B As Characterized by Nuclear Magnetic Resonance and X-ray CrystallographyBiochemistry, 2009
- Modulation of the Oligomerization State of p53 by Differential Binding of Proteins of the S100 Family to p53 Monomers and TetramersJournal of Biological Chemistry, 2009
- A facile method for expression and purification of the Alzheimer’s disease‐associated amyloid β‐peptideThe FEBS Journal, 2009
- Structural and functional insights into RAGE activation by multimeric S100BThe EMBO Journal, 2007
- Modulation of neurodegeneration by molecular chaperonesNature Reviews Neuroscience, 2005
- Protein aggregation and neurodegenerative diseaseNature Medicine, 2004